Aquapharm & Medical Research Council evaluate EndoSeaRch- a new approach to digestive health
Scottish biotechnology firm Aquapharm has joined forces with the Medical Research Council’s Human Nutrition Research unit (MRC HNR) in Cambridge to evaluate the potential of a new approach to digestive health, called EndoSeaRch™.
The two parties are seeking to modulate certain bacterial populations of the gastrointestinal tract with orally delivered synthetic minerals in models of Inflammatory Bowel Disease (IBD). These may include food supplements and ingredients for humans and farm animals, as well as novel therapeutic agents that could lead to better treatment, or even prevention of, human gut diseases such as irritable bowel syndrome (IBS) and IBD.
EndoSeaRch™ represents the first in-vivo application for SeaRch™ – a patented Aquapharm technology for stimulating bacteria that form bio-films to maximise the range of bio-chemicals they produce in response to oxidative stress. The agents used by Aquapharm to induce stress include a variety of trace elements such as iron, copper and manganese, which are essential micronutrients of the human diet. The bio-chemicals produced by the bacteria include a wide range of natural anti-bacterial, anti-inflammatory and anti-oxidant agents, which formed the historic defences used by the organisms to overcome environmental and competitive stresses.